Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA in serum~* AST/ALT greater than the upper limit of normal range~* HVPG \>5 mm Hg~* Non-response or contraindication to a standard course of antiviral therapy~Exclusion Criteria:~* Active alcoholism~* HIV infection~* Serum creatinine \>1.2 mg/dl, hemoglobin \<11 g/dl, hemolysis, symptomatic ischemic heart disease or cerebrovascular disease~* Decompensated chronic liver disease~* Pregnancy~* Hypersensitivity to the drugs of the study~* Severe concomitant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ribavirin (Type: EXPERIMENTAL): Ribavirin 1000-1200 mg qd
- Colchicine (Type: ACTIVE_COMPARATOR): Colchicine 0.5 mg bd

Based on this trial design, predict the completion outcome and termination type (if applicable).